Marijuana is prescribed to help ease chronic pain and control nausea in cancer patients, but legal red tape has made more ...

Move doesn’t federally legalize marijuana but would ease tax burdens for cannabis businesses and facilitate more medical ...

Moving cannabis to a category of drugs that includes some common medicines will have implications for research, businesses ...

The order to place cannabis in the same category as Tylenol with codeine marks the most significant change in US drug policy ...

While federally decriminalizing marijuana could have “the greatest effect” on Nevada’s legal cannabis industry, reclassifying it as a less-dangerous drug could ease tax-related burdens for the ...

The move to reclassify cannabis from a Schedule I to a Schedule III drug could spark new studies into pain, aging and women's health, Dr. Staci Gruber tells GBH's All Things Considered.

President Trump signed executive order reclassifying cannabis from Schedule 1 to Schedule 3, expanding research opportunities amid mixed congressional reactions.

The executive order is significant to the cannabis industry for its support of more research, stronger standards and ending negative stereotypes.

Industry members are cautiously optimistic that rescheduling marijuana to a lower tier is one step closer to full ...

Trump's executive order to expedite reclassifying cannabis means wider access to marijuana, and that it could be used like ...

President Trump issued an executive order calling on the DEA to reclassify cannabis as a Schedule III controlled substance.

When Canada legalized cannabis in October 2018, there were many concerns about its potential impacts. One of them involved ...